WiseTech, Pro Medicus and NEXTDC: What Their FY26 Financials Reveal

Sonal Goyal

14 September 2026 06:53 PM AEST

WiseTech, Pro Medicus and NEXTDC: What Their FY26 Financials Reveal

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

WiseTech Global (ASX:WTC), Pro Medicus (ASX:PME) and NEXTDC (ASX:NXT) reported different financial profiles during FY26. WiseTech recorded substantial Revenue and Earnings growth, Pro Medicus maintained high profitability alongside double-digit revenue growth, while NEXTDC reported higher-scale revenue and EBITDA as its data-centre Business continued to develop.

WiseTech Global

WiseTech reported FY26 revenue growth of 79%, with revenue from e2open contributing approximately AUD 541.2 million during the period.

Underlying EBITDA increased 56% to approximately AUD 644.5 million.

Underlying net profit after tax reached AUD 313.5 million, representing growth of 29%.

Cash generation also increased during the year. Free Cash Flow reached approximately AUD 410.7 million, while underlying free cash flow was AUD 489.6 million.

Underlying free cash flow increased 67%, placing cash generation ahead of the growth rate recorded in underlying profit.

From a financial perspective, future reporting will provide further information on whether the expanded revenue base translates into sustained EBITDA, profit and cash-flow growth.

Pro Medicus

Pro Medicus reported FY26 revenue of approximately AUD 261.7 million, representing growth of 22.9%.

Underlying net profit after tax increased 24.1% to approximately AUD 144.7 million.

Underlying EBIT Margin reached 74.9%, highlighting the comparatively high profitability of the company's software-based operating model.

The Balance Sheet remained debt-free at the end of the period, with cash and other financial Assets of approximately AUD 252.3 million.

Revenue and profit growth remained closely aligned during FY26, while the EBIT margin showed that a substantial proportion of additional revenue continued to flow through to operating earnings.

The combination of double-digit revenue growth, a high EBIT margin and the absence of Debt provides a different financial profile from more capital-intensive growth businesses.

Future results will indicate whether revenue growth and operating margins can remain at similar levels as the company's revenue base expands.

NEXTDC

NEXTDC reported FY26 net revenue of approximately AUD 405 million.

Underlying EBITDA reached approximately AUD 248.8 million.

The relationship between revenue and EBITDA reflects the contribution of existing data-centre capacity, although NEXTDC's financial model differs significantly from the software businesses because it requires substantial ongoing Capital investment.

The supplied material does not provide a confirmed FY26 statutory profit or loss figure, free cash flow figure or verified forward capital-expenditure guidance from a primary source. These figures have therefore not been included.

This means the financial assessment is necessarily narrower than for WiseTech and Pro Medicus.

Financial Performance

The three companies show materially different financial characteristics.

WiseTech recorded the largest percentage increase in revenue and substantial growth in EBITDA, Underlying Profit and free cash flow. Its financial performance during FY26 was also influenced by the larger consolidated revenue base.

Pro Medicus reported lower absolute revenue than WiseTech but maintained a 74.9% underlying EBIT margin. Its underlying profit growth slightly exceeded revenue growth, while the company remained debt-free.

NEXTDC generated AUD 405 million in net revenue and AUD 248.8 million in underlying EBITDA. However, the absence of confirmed statutory profit and cash-flow figures in the supplied material limits direct comparison with the other two companies.

Key Risks

WiseTech's financial results may be affected if operating expenses rise faster than revenue or if the difference between statutory and underlying profitability remains elevated.

Pro Medicus faces the challenge of maintaining high operating margins while continuing to expand revenue. Slower revenue growth could have a greater impact on earnings expectations given its existing profitability profile.

NEXTDC's capital-intensive model means revenue and EBITDA need to be considered alongside depreciation, financing costs, Capital Expenditure and cash flow. These measures are important when assessing overall financial performance.

What Investors May Monitor Through the Rest of 2026

For WiseTech, revenue growth, underlying EBITDA, underlying NPAT and free cash flow will provide the clearest measures of financial progression.

For Pro Medicus, revenue growth, EBIT margins, underlying NPAT and cash balances remain the primary financial indicators.

For NEXTDC, future statutory earnings, EBITDA, capital expenditure, financing costs and cash-flow disclosures will provide a more complete assessment of financial performance.

Overall, WiseTech, Pro Medicus and NEXTDC represent three different financial profiles. WiseTech combines rapid revenue expansion with increasing cash generation, Pro Medicus pairs double-digit growth with high operating margins, while NEXTDC operates a more capital-intensive model where EBITDA must ultimately be assessed alongside investment requirements and financing costs.

FAQs

Q: What underlying EBITDA did WiseTech report for FY26?

A:WiseTech reported underlying EBITDA of approximately AUD 644.5 million.

Q: What was Pro Medicus' FY26 underlying EBIT margin?

A:Pro Medicus reported an underlying EBIT margin of 74.9%.

Q: What financial figures were reported for NEXTDC in FY26?

A:The supplied material reports net revenue of approximately AUD 405 million and underlying EBITDA of AUD 248.8 million.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.